Compare Crown Castle International Corp (CCI) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Cassava Sciences Inc — how do they compare? Crown Castle International Corp trades at $73.7 (market cap $31.33B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Crown Castle International Corp is far larger — about 656.1× Cassava Sciences Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CCI | FLNA | |
|---|---|---|
Market Cap | $31.33B | $47.75M |
Sector | Real Estate | Health |
52-Week High | $103.79 | $4.64 |
52-Week Low | $73.61 | $0.87 |
Enterprise Value | $53.69B | -$34.93M |
Dividend Yield | 5.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $73.61, down 2.62% on the day and near 52-week lows. The technical picture is bearish with mixed fundamentals - strong profitability margins (73.7% gross margin) but negative shareholder equity and high debt levels. Recent Q2 2026 earnings beat expectations with AFFO of $1.13 per share, while the company transitions to a pure-play U.S. tower operator following asset sales.
The stock presents a contrarian opportunity with 50% analyst buy ratings and a $95.29 price target suggesting 29% upside, but faces significant debt burden and execution risks from strategic shifts. The 5.5% dividend yield provides income support while investors await operational improvements.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
